Irritable Bowel Syndrome News and Research RSS Feed - Irritable Bowel Syndrome News and Research

Irritable bowel syndrome (IBS) is a common disorder that affects the large intestine, often causing bouts of cramping, abdominal pain, bloating, diarrhea and constipation.

IBS is not curable but, in most cases, people learn to live with and control the condition by managing diet, lifestyle and stress levels. Medications to treat diarrhea, pain killers or drugs that relieve painful bowel spasms may also be used.

The cause of IBS is not yet clear but it is linked to changes in the way food is moved through the bowel. In healthy people, layers of muscle lining the intestinal wall contract and relax in a coordinated manner to move food from the stomach, through the colon and into the rectum. When an individual has IBS, however, the contractions are unusually strong and food is passed through the intestine too quickly which leads to diarrhea and a build up of gas.

Triggers for IBS range from pressure on the intestines to certain foods such as chocolate or carbonated drinks, hormonal changes such as during the menstrual cycle and emotional changes such as an increase in stress.

IBS can be painful and debilitating if not treated appropriately, negatively impacting on a person’s quality of life. However, with appropriate treatment individuals with IBS should be able to live a full and active life.
GMP protein can improve gastrointestinal health by protecting digestive system from pathogens

GMP protein can improve gastrointestinal health by protecting digestive system from pathogens

The protein glycomacropeptide (GMP) is derived from whey, the liquid by-product of the cheese-making process. GMP contains low amounts of the amino acid phenylalanine. Individuals who suffer from phenylketonuria—a metabolic disorder that causes cognitive impairment when phenylalanine level is too high—can use GMP as an alternative protein source. GMP supplementation has also been observed to improve gastrointestinal health by protecting the digestive system from pathogens and by having an anti-inflammatory effect. [More]
Ardelyx reports net income of $9.0 million for second quarter 2015

Ardelyx reports net income of $9.0 million for second quarter 2015

Ardelyx, Inc., a clinical-stage biopharmaceutical company focused on gastrointestinal and cardio-renal diseases, today announced financial results for the second quarter ended June 30, 2015. [More]
Intrexon, Synthetic Biologics form ECC to develop and commercialize novel biotherapeutics for phenylketonuria

Intrexon, Synthetic Biologics form ECC to develop and commercialize novel biotherapeutics for phenylketonuria

Intrexon Corporation, a leader in synthetic biology, and Synthetic Biologics, Inc., a clinical-stage company focused on developing therapeutics to protect the microbiome while targeting pathogen-specific diseases, today announced an Exclusive Channel Collaboration (ECC) to pursue the development and commercialization of novel biotherapeutics for the treatment of patients with phenylketonuria (PKU), a serious and debilitating metabolic disorder. [More]
Sheffield researchers win national awards for pioneering work on coeliac disease, IBS

Sheffield researchers win national awards for pioneering work on coeliac disease, IBS

Researchers at Sheffield Teaching Hospitals have received awards for their work investigating coeliac disease and irritable bowel syndrome, two common gastrointestinal conditions. [More]
Groundbreaking experimental therapy has ability to suppress ulcerative colitis

Groundbreaking experimental therapy has ability to suppress ulcerative colitis

UCLA scientists have discovered a groundbreaking experimental therapy that has the ability to suppress the development of ulcerative colitis (UC), a disease which causes inflammation in the digestive tract and colon cancer. The treatment utilizes a chemical inhibitor able to block an RNA molecule (microRNA-214) involved in the transmission of genetic information. [More]
SUNY Downstate Medical Center researchers identify ALPIM syndrome as new spectrum disorder

SUNY Downstate Medical Center researchers identify ALPIM syndrome as new spectrum disorder

The relationship between mental and physical health is well established. But when mental and physical illnesses co-occur, patients' accounts of physical illness are sometimes arbitrarily discredited or dismissed by physicians. [More]
Study demonstrates the important role of placebo effect in medical care

Study demonstrates the important role of placebo effect in medical care

The "placebo effect" is often described as events that occur when patients show improvement from treatments that contain no active ingredients. [More]
Study provides insights into the cause of irritable bowel syndrome

Study provides insights into the cause of irritable bowel syndrome

A team comprised of scientists at VIB, KU Leuven and UZ Leuven has made significant progress in uncovering the connection between psychological factors and the immune system. Their findings are based on an investigation of a massive drinking water contamination incident in Belgium in 2010, and are now published in the leading international medical journal Gut. [More]
Pinaverium offers quick relief from IBS symptoms

Pinaverium offers quick relief from IBS symptoms

Pinaverium offers quick and effective relief of irritable bowel syndrome (IBS) symptoms, according to clinical trial results published in Clinical Gastroenterology and Hepatology, the official clinical practice journal of the American Gastroenterological Association. [More]
Synthetic Biologics announces initiation of SYN-010 Phase 2 clinical trial for treatment of IBS-C

Synthetic Biologics announces initiation of SYN-010 Phase 2 clinical trial for treatment of IBS-C

Synthetic Biologics, Inc., a clinical-stage company focused on developing therapeutics to protect the microbiome while targeting pathogen-specific diseases, reported the initiation of a Phase 2 clinical trial of its proprietary SYN-010 for the treatment of irritable bowel syndrome with constipation (IBS-C). [More]
Concordia Healthcare's common shares to begin trading on NASDAQ under symbol CXRX

Concordia Healthcare's common shares to begin trading on NASDAQ under symbol CXRX

Concordia Healthcare Corp., a diverse healthcare company focused on legacy pharmaceutical products and orphan drugs, today announced that its common shares will begin trading on the NASDAQ Global Select Market on June 29, 2015 under the symbol CXRX. [More]
A gastroenterologist guide to probiotics

A gastroenterologist guide to probiotics

In recent years, scientists have introduced us to a paradigm shift in the microscopic world. We've moved from thinking about all bacteria as bad guys to be wiped out with antibiotics and hand sanitizer to recognizing that some microbes are helpers, good bacteria that live in our GI tract (and all over our bodies) that keep us healthy. [More]
Ardelyx signs termination agreement with AstraZeneca, regains rights to portfolio of NHE3 inhibitors

Ardelyx signs termination agreement with AstraZeneca, regains rights to portfolio of NHE3 inhibitors

Ardelyx, Inc., a clinical-stage biopharmaceutical company focused on cardio-renal, gastrointestinal and metabolic diseases, today announced that it has entered into a termination agreement with AstraZeneca, such that all the rights to Ardelyx's portfolio of NHE3 inhibitors, including Ardelyx's lead product candidate, tenapanor, are returned to Ardelyx. [More]
Women who suffer from fibromyalgia benefit from hyperbaric oxygen therapy

Women who suffer from fibromyalgia benefit from hyperbaric oxygen therapy

Women who suffer from fibromyalgia benefit from a treatment regimen in a hyperbaric oxygen chamber, according to researchers at Rice University and institutes in Israel. [More]
Actavis announces FDA approval of VIBERZI (eluxadoline) for IBS-D treatment

Actavis announces FDA approval of VIBERZI (eluxadoline) for IBS-D treatment

Actavis plc announced today that VIBERZI (eluxadoline) was approved by the Food and Drug Administration as a twice-daily, oral treatment for adults suffering from irritable bowel syndrome with diarrhea (IBS-D). VIBERZI (eluxadoline) has mixed opioid receptor activity, it is a mu receptor agonist, a delta receptor antagonist, and a kappa receptor agonist. [More]
Salix Pharmaceuticals receives FDA approval for Xifaxan 550 mg to treat IBS-D in adults

Salix Pharmaceuticals receives FDA approval for Xifaxan 550 mg to treat IBS-D in adults

Valeant Pharmaceuticals International, Inc. announced that its wholly owned subsidiary, Salix Pharmaceuticals, Inc., has received approval from the U.S. Food and Drug Administration for Xifaxan 550 mg for the treatment of IBS-D in adults. [More]

Ardelyx reports positive results from tenapanor Phase 2b clinical trial in IBS-C patients

Ardelyx, Inc., a clinical-stage biopharmaceutical company focused on cardio-renal, gastrointestinal, and metabolic diseases, today presented Phase 2b clinical trial results that demonstrated statistically significant and clinically meaningful improvement in IBS-C symptoms for tenapanor-treated patients compared to patients receiving placebo. [More]
Live, multi-strain probiotic drink may benefit people with ulcerative colitis

Live, multi-strain probiotic drink may benefit people with ulcerative colitis

People with ulcerative colitis may benefit from taking the live, multi-strain probiotic drink, Symprove, to reduce intestinal inflammation, according to the results of a new study presented today at Digestive Disease Week 2015. [More]

Commonwealth announces availability of new ELISA-based blood test to quickly and reliably diagnose IBS

Commonwealth Laboratories, Inc. announced today the availability of IBSchek, a new blood test designed to help physicians quickly and reliably diagnose Irritable Bowel Syndrome (IBS). [More]
Simple blood tests diagnose irritable bowel syndrome quickly and accurately

Simple blood tests diagnose irritable bowel syndrome quickly and accurately

Millions of people afflicted by irritable bowel syndrome can now be diagnosed quickly and accurately with two simple blood tests developed by a Cedars-Sinai gastroenterologist. [More]
Advertisement
Advertisement